Drexel Morgan & Co’s AbbVie ABBV Stock Holding History

Drexel Morgan & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$413K	Hold	1,900	–	–	0.06%	52
2025 Q4	$434K	Hold	1,900	–	–	0.07%	49
2025 Q3	$440K	Hold	1,900	–	–	0.07%	46
2025 Q2	$353K	Hold	1,900	–	–	0.06%	47
2025 Q1	$398K	Hold	1,900	–	–	0.08%	46
2024 Q4	$338K	Hold	1,900	–	–	0.07%	47
2024 Q3	$375K	Hold	1,900	–	–	0.07%	48
2024 Q2	$326K	Buy	1,900 +291	+18%	+$48.2K	0.07%	47
2024 Q1	$293K	Hold	1,609	–	–	0.06%	47
2023 Q4	$249K	Buy	1,609 +259	+19%	+$37.8K	0.06%	47
2023 Q3	$201K	Buy	+1,350	New	+$198K	0.05%	47
2023 Q2	–	Sell	-1,350	Closed	-$215K	–	46
2023 Q1	$215K	Hold	1,350	–	–	0.05%	45
2022 Q4	$218K	Buy	+1,350	New	+$207K	0.04%	45
2022 Q3	–	Sell	-1,350	Closed	-$207K	–	45
2022 Q2	$207K	Hold	1,350	–	–	0.06%	44
2022 Q1	$219K	Buy	+1,350	New	+$196K	0.06%	43
2021 Q2	–	Sell	-4,432	Closed	-$480K	–	72
2021 Q1	$480K	Hold	4,432	–	–	0.12%	68
2020 Q4	$475K	Hold	4,432	–	–	0.13%	65
2020 Q3	$388K	Hold	4,432	–	–	0.14%	70
2020 Q2	$436K	Hold	4,432	–	–	0.16%	66
2020 Q1	$338K	Sell	4,432 -1,120	-20%	-$95.4K	0.13%	69
2019 Q4	$492K	Hold	5,552	–	–	0.37%	55
2019 Q3	$420K	Sell	5,552 -450	-7%	-$30.9K	0.32%	61
2019 Q2	$437K	Buy	6,002 +450	+8%	+$35.4K	0.34%	59
2019 Q1	$448K	Hold	5,552	–	–	0.4%	57
2018 Q4	$511K	Hold	5,552	–	–	0.51%	49
2018 Q3	$525K	Hold	5,552	–	–	0.46%	55
2018 Q2	$514K	Buy	5,552 +252	+5%	+$24.6K	0.51%	52
2018 Q1	$502K	Hold	5,300	–	–	0.52%	52
2017 Q4	$513K	Hold	5,300	–	–	0.5%	53
2017 Q3	$471K	Hold	5,300	–	–	0.48%	53
2017 Q2	$384K	Sell	5,300 -225	-4%	-$15.1K	0.39%	60
2017 Q1	$360K	Hold	5,525	–	–	0.4%	62
2016 Q4	$346K	Hold	5,525	–	–	0.41%	60
2016 Q3	$348K	Hold	5,525	–	–	0.39%	64
2016 Q2	$342K	Hold	5,525	–	–	0.39%	66
2016 Q1	$315K	Hold	5,525	–	–	0.37%	67
2015 Q4	$327K	Hold	5,525	–	–	0.36%	73
2015 Q3	$300K	Hold	5,525	–	–	0.39%	67
2015 Q2	$372K	Hold	5,525	–	–	0.44%	62
2015 Q1	$323K	Hold	5,525	–	–	0.34%	79
2014 Q4	$361K	Hold	5,525	–	–	0.41%	64
2014 Q3	$319K	Hold	5,525	–	–	0.39%	71
2014 Q2	$312K	Hold	5,525	–	–	0.38%	73
2014 Q1	$284K	Hold	5,525	–	–	0.36%	69
2013 Q4	$291K	Hold	5,525	–	–	0.39%	68
2013 Q3	$247K	Hold	5,525	–	–	0.34%	73
2013 Q2	$229K	Buy	+5,525	New	+$242K	0.38%	71

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Drexel Morgan & Co's ABBV Position: Q1 2026 in Review

Drexel Morgan & Co held its AbbVie (ABBV) position steady in Q1 2026 at 1,900 shares worth $413K. The position accounts for 0.06% of the portfolio, ranked #52.

Drexel Morgan & Co first reported a position in ABBV in Q2 2013 and has held it in 47 quarters since. The position peaked at $525K in Q3 2018. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Drexel Morgan & Co held 1,900 shares of AbbVie worth $413K as of Q1 2026.
Drexel Morgan & Co left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.06% of Drexel Morgan & Co's portfolio in Q1 2026, its #52 holding.
Drexel Morgan & Co first reported a position in AbbVie in Q2 2013 and has held it in 47 quarters since.
Drexel Morgan & Co's AbbVie position peaked at $525K in Q3 2018.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Drexel Morgan & Co's 13F filing for Q1 2026, filed 11 May 2026.